FISCAL ESTIMATE FORM			1999 Session
		LRB # -4189/	/1
⊠ ORIGINAL	☐ UPDATED	INTRODUCTI	ON # SB335
CORRECTED	□ SUPPLEMENTAL	Admin. Rule#	
Subject Prescription Drug Assistance for	or the Elderly		
Fiscal Effect			
State:   No State Fiscal Effect  Check columns below only if bill makes a direct appropriation  or affects a sum sufficient appropriation.			☑ Increase Costs - May be possible to Absorb Within Agency's Budget ☐ Yes ☑ No
<ul> <li>☐ Increase Existing Appropriation</li> <li>☐ Decrease Existing Appropriation</li> <li>☐ Decrease Existing Revenues</li> <li>☑ Create New Appropriation</li> </ul>			☐ Decrease Costs
Local: ⊠ No local government	costs		1
□ Increase Costs     □ Permissive □ Mand	3. ☐ Increase Re		5. Types of Local Governmental Units Affected: ☐ Towns ☐ Villages ☐ Cities
2. Decrease Costs	4. ☐ Decrease R	levenues	☐ Counties ☐ Others
☐ Permissive ☐ Mand	latory   Permissi		☐ School Districts ☐ WTCS Districts  Ch. 20 Appropriations
Fund Sources Affected  ☑ GPR ☐ FED ☑ PR	O □PRS □ SEG □	SEG-S	Sn. 20 Арргорнацон <b>s</b>
Assumptions Used in Arriving at Fis			· .
See Attached Narrative.			
			·
)			
Long-Range Fiscal Implications:			
		1/	hone No. Date
Prepared By: / Phone # / Age Richard T. Chao / 267-0356		orized Signature / Tel p	m Kusati)
DHFS/OSF	Joh	n Kiesow, 266-962	01/25/2000

#### **Bill Summary**

Senate Bill 335 provides state assistance to pay a significant portion of the cost of prescription drugs for most elderly in Wisconsin. In addition, enrollees would pay 25% coinsurance for the cost of drugs, and a \$5 or \$10 co-payment for each filled prescription. Eligibility includes all Wisconsin residents age 65 and over who are ineligible for Medicaid and whose income does not exceed \$50,000 if single or \$75,000 if married. The state would pay 75% of the cost of prescription drugs up to \$10,000 annually. Recipients would pay the remaining 25% in addition to a \$5 co-payment for generic drugs and \$10 for brand name drugs.

The bill mandates that pharmacies charge enrollees no more than the Medicaid rate for prescription drugs. Drugs dispensed under this program would be reimbursed at the Medicaid rate of AWP – 10% plus a dispensing fee or Maximum Allowable Cost. In order for its products to be made available through this program, a manufacturer must enter into a rebate agreement with the state to provide rebates equal to those provided under the Medicaid program. The bill creates a sum sufficient appropriation to fund the program benefits. In addition, the bill appropriates \$1 million per year for the administration of the program.

#### Fiscal estimate

#### Administrative expenses

The bill appropriates \$1,000,000 in general purpose revenues (GPR) for administration of the prescription drug assistance program. This funding level significantly underestimates the cost of administering the plan. Administering this program would involve evaluating eligibility for over 600,000 people each year, developing a system that can process claims with deductibles, co-insurance, and co-payments, processing approximately 12 million claims per year, administering lines of communication and assistance for recipients and providers, and negotiating and collecting rebates from manufacturers. Assuming these tasks could be completed at a cost of \$20 per potential eligible per year, these administrative costs would be approximately \$12 million annually. The Department also anticipates a one-time administrative cost of \$2 million for information system start-up costs.

In addition, the Department estimates that an additional 4.5 FTE will be needed to administer the program. The estimated total annual cost for these positions is \$233,200, with one-time costs of \$21,300. A table summarizing the fiscal effects of the necessary positions is attached.

#### **Total Cost of the Program**

In the first full year of program implementation, SFY 02, the estimated annualized net cost of the program is expected to be \$151,198,900. This figures includes \$228,371,600 in state assistance for benefits, \$12,233,200 in annual administrative expenses, the collection of \$46,015,200 in copayment revenues, and the collection of \$43,390,600 in manufacturers rebates. If collection of manufacturer rebates is not possible, the estimated total annualized cost of the program is approximately \$194 million in SFY 02. A more detailed explanation can be found in the attached worksheets.

#### **Major Assumptions**

Current trends indicate that Medicaid drug expenditures have been increasing by approximately 15% per year. The proposed program pays for all drugs covered by the Wisconsin Medicaid program, which operates under an "open formulary" system. Without any significant statutory or policy changes at the federal or state levels, it is assumed that the rate of increase for drug expenditures for this program will rise at 15% per year.

This estimate assumes a 19% rebate from drug manufacturers. The bill mandates that in order for its products to be made available through this program, a manufacturer must enter into a rebate agreement with the state to provide rebates equal to those provided under the Medicaid program. However, unlike the Medicaid program, there is no federal law mandating that manufacturers provide rebates for this type of program.

This estimate assumes no "crowd out" of current insurance coverage for prescription drugs for the elderly. However, because the proposed program provides benefits with no enrollment cost, it is possible that elderly individuals who currently have insurance coverage for drugs, e.g. Medigap prescription drug riders, may choose to drop or modify their current insurance coverage. Any occurrence of "crowd out" would increase the total benefits cost of the program and could be as high as an additional \$112.3 million per year.

#### Other assumptions for this estimate include:

- A program participation rate of 75% for all eligible people with no "ramp up" for enrollment.
- An annual out-of-pocket drug cost of \$1,200 for recipients without insurance.
- A 23% discount in Medicaid reimbursement levels (AWP-10%) below retail prices.
- The out-of-pocket expense of recipients with drug coverage is 35% of recipients without drug coverage.
- An average of 27.4 prescriptions per year for eligible individual.
- A 2:1 ratio of generic to brand name prescriptions.

# **Total Costs for First Full Year of Operation (SFY 02)**

	\$ 151.198.912	Net Total Cost for First Full Year of Operation (SFY 02)
	\$ 43,390,604	Manufacturers Rebate
Revenues	\$ 46,015,240	Copayments Collected
	\$ 12,233,155	Adminstrative Expenses
,	\$ 228,371,601	Total Cost of Benefits Assistance
Expenses		

# **Population and State Benefits Estimates**

#### **Estimates of Potential Enrollees**

700,000	Approximate Total Elderly Population in State
608,300	Total Potential Eligibles (86.9% of total population)
215,900	Potential Eligibles without drug coverage (35.5% of Total)
392,400	Potential Eligibles with drug coverage (64.5% of Total)

#### State Assistance for Enrollees Without Drug Coverage

215,900	Potential eligibles without drug coverage
161,925	Enrollees without drug coverage (assumes 75% participation)
\$1,200	Annual drug cost per enrollee
\$924	Annual drug cost per enrollee at AWP - 10% (23% discount)
\$693	State share of annual drug cost (75% of total)
\$112,214,025	Annual state assistance for enrollees without drug coverage

# State Assistance for Enrollees With Drug Coverage

392,400	Total eligibles with drug coverage
60,000	Less Medicaid Recipients
332,400	Potential drug assistance program eligibles with drug coverage
249,300	Enrollees with drug coverage (assumes 75% participation)
\$420	Annual out-of-pocket drug cost per enrollee (35% of 1200)
\$323	Annual drug cost per enrollee at AWP - 10% (23% discount)
\$243	State share of annual drug cost (75% of total)
\$60,467,715	Annual state assistance for enrollees with drug coverage
\$112,297,185	Annual drug expenses paid with other insurance coverage.
	(Potential crowd out amount)

#### **Total State Assistance**

\$112,214,025 \$60,467,715	Annual state assistance for enrollees with drug coverage  Annual state assistance for enrollees with drug coverage
\$172,681,740 \$32,809,531	Cost of state assistance Less Drug Manufactures Rebates
\$139.872.209	Net Cost of Drug Purchase (SFY 00 dollars)

# **Estimates of Revenues from Co-Payments**

#### Generic Co-Payments for Enrollees without Drug Coverage

Enrollees without drug coverage (assumes 100% participation) Generic scripts per year per enrollee (2/3 of MA avg)
Generic scripts per year
Generic script co-payment
Generic co-payment revenue from enrollees without drug coverage

#### Brand Co-Payments for Enrollees without Drug Coverage

161,925	Enrollees without drug coverage (assumes 100% participation)
9.3	Brand scripts per year per enrollee (2/3 of MA avg)
1,511,300	Brand scripts per year
\$10	Brand script co-payment
\$15,113,000	Brand co-payment revenue from enrollees without drug coverage

#### Generic Co-Payments for Enrollees with Drug Coverage

249,300	Enrollees without drug coverage (assumes 100% participation)
6.4	Generic scripts per year per enrollee (2/3 MA avg *35%)
1,593,858	Generic scripts per year
\$5	Generic script co-payment
\$7,969,290	Generic co-payment revenue from enrollees with drug coverage

#### Brand Co-Payments for Enrollees with Drug Coverage

249,300	Enrollees without drug coverage (assumes 100% participation)
3.3	Brand scripts per year per enrollee (2/3 of MA avg * .35%)
814,380	Brand scripts per year
\$10	Brand script co-payment
\$8,143,800	Brand co-payment revenue from enrollees with drug coverage

#### **Total Co-Payment Revenue**

\$14,789,150	Generic co-payment revenue from enrollees without drug coverage
\$15,113,000	Brand co-payment revenue from enrollees without drug coverage
\$7,969,290	Generic co-payment revenue from enrollees with drug coverage
\$8,143,800	Brand co-payment revenue from enrollees with drug coverage

\$46,015,240 Total Co-Payment Revenue

#### **Benefits Costs**

# Cost for First 6 Months -- January 2001 to June 2001

Total state assistance Less Drug Rebates	\$172,681,740 \$32,809,531
Annual Benefits Cost (SFY 00 dollars) Estimated rate of increase in drug expenditures	\$139,872,209 1.15
Annual Benefits Cost in SFY 01 dollars Less Co-payment revenue	\$160,853,041 \$46,015,240
Net Annual Benefits Cost in SFY 01 dollars Portion of year in operation	\$114,837,801 0.5
Total Cost for First 6 Months of Program (SFY 01)	\$57,418,900

# Cost for the First Full Year of Operation -- July 2001 to June 2002

Total state assistance (SFY 00 dollars)	\$ 172,681,740 1.32
Estimated rate of increase in drug expenditures  Total state assistance (SFY 02 dollars)	\$ 228,371,601
Total state assistance (SFT 02 dollars)	Ψ 220,071,001
Less Drug Rebates (SFY 00 dollars)	\$ 32,809,531
Estimated rate of increase in drug expenditures	1.32
Drug Rebates (SFY 02 dollars)	\$ 43,390,604
Total state assistance (SFY 02 dollars)	\$228,371,601
Less Drug Rebates (SFY 02 dollars)	\$43,390,604
Less Co-payment revenue	\$46,015,240
Total Benefit Cost for First Full Year of Program (SFY 02)	\$138,965,757

# Administrative Expenses

												Ī		ī				
Classification		Approp	FTE		\$/hr	Š	Salary		Fringe	SS	S & S	ď	Rent	Services		Total	ő	One-time
	Section Chief		1.00	<del>69</del>	17.81 \$	€9	37,045 \$	<del>69</del>	13,188 \$	<b>.</b>	1,200 \$ 2,000	€9	3,000	\$3,100		\$ 56,533 \$	<del>69</del>	4,800
	IS Consultant		1.00	<del>∽</del> ,	17.60 \$	<del>∽</del>	36,608 \$	€9	13,032 \$	ıΔ	1,200 \$ 2,000	<del>69</del>	3,000	\$3,100	€9	55,940 \$	<del>69</del>	4,800
	Program and Planning Anaylst 5		2.00	<del>69</del>	16.05	<del>69</del>	.\$ 892,999	Ġ	23,769 \$	<b>'A</b>	2,400 \$ 4,000	<del>69</del>	1,000	\$6,200	<del>69</del>	\$ 103,137 \$	<del>69</del>	009'6
	Prog Assist -2		0.50	<del>∽</del>	10.21	<del>\$</del>	10,615 \$	<del>69</del>	3,779 \$	<b>6</b> ₽	009	€9	000 \$ 1,000	\$1,550	<del>⇔</del>	\$ 17,544 \$	↔	2,400
	Total		4.50			151,	151,036.08 53,768.84		,768.84	5,40(	00.0	6,00	0.00	5,400.00 9,000.00 13,950.00 233,154.92 21,600.00	233,	154.92	21,6	00:00

		\$ 12,000,000	\$ 233,155	\$ 12,233,155	\$ 2,000,000 \$ 21,600	\$ 2,021,600
\$20/Recipient	000'009		'		,	
Ongoing Eligibility and Administrative Expenses	Number of Recipients	Recipient Administrative Expense	Personnel Expense	Total On-going Administrative Expenses	One-time Systems Modification One-time Staff Expenses	Total One-time Administrative Expenses

<b>FISCAL ESTIMA</b>	TE WORKSHEET	Detailed Estim	ate of Annual Fiscal Ef	ect				1999 S	ession
☑ ORIGINAL	☐ UPDATED	LRB #-4189	/1					Admi	n. Rule
☐ CORRECTED	☐ SUPPLEMENTAL		TION # SB 33:	5				1	
Subject							· · · · · ·	1	
Prescription Drug	g Assistance for the	Elderly							
	sts or Revenue Imp	acts for State and/o	or Local Governmen	t (do	not includ	e in annu	alized	fiscal ef	fect):
\$2,021600									
II. Annualized	Costs:				Annualized	Fiscal impa	act on	State fun	ds from:
					Increased (	Costs		Decrease	d Costs
	s <b>by Category</b> perations - Salaries	and Fringes		\$			\$	-	
	porduorio dalario	- Line i i i i i i i i i i i i i i i i i i					<u> </u>		
(FTE Po	osition Changes)				( 4.5	FTE)		(-	FTE
					12,233,2	200			
State O	perations - Other C	osts		<u> </u>	12,233,2	.00	├		
Local A	ssistance							-	
							T		
Aids to	Individuals or Orga	nizations			228,371,	,600	<u> </u>	-	
ΤΟ:	TAL Chata Casta bu	Catagoni		\$	240,604,	800	\$	-	
	TAL State Costs by			+	Increased		1	Decrease	d Costs
B. State Costs	s by Source of Fur	ius							
GPR				\$	240,604,	,800	\$		
FED								-	
1 20				$\vdash$					
PRO/PF	RS								
070/05								_	
SEG/SE		leed a second will income	roana or dooragea stata		Increased	Rev.	┼	Decrease	ed Rev.
State Reve	nues Complete this on revenues (e.g., ta	ny when proposal will incl ax increase, decrease in I	icense fee, etc.)						
GPR Ta	axes			\$			\$	•	
GPR Ea	arned	•						-	
				<del>                                     </del>					
FED								-	
220/21	20				89,405,8	200		_	
PRO/PI	<del></del>			<u> </u>	00,400,0		+	<u> </u>	
SEG/SE	EG-S						:	•	
TO	TAL State Revenue	S		\$			\$	•	
		NET ANNUAL	LIZED FISCAL IMP	ACT	-		LOC	• 1 1	
		•	<u>STATE</u>	00.0	20 1	r	<u> </u>	<u>/^\L</u>	
NET CHANGE IN	N COSTS	\$	151,1	<del>9</del> 8,9(	טט ג	Φ			
NET CHANGE IN	N REVENUES	\$			;	\$			
Prepared By: /	Phone # / Agency N	lame	Authorized Signatur			<del></del>		Date	
Richard T. Cl	hao / 267-0356				Scoot	J		1-2	6-00
DHFS/OSF			John Kiesow,	200-	9022			,	<u>-</u>